Core Viewpoint - MiNK Therapeutics, Inc. is set to release its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Group 1: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [3]. - The company is advancing a pipeline of both native and next-generation engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [3]. - MiNK Therapeutics is headquartered in New York, NY, and provides regular updates on important information for investors through its website and social media channels [3]. Group 2: Conference Call Details - The conference call will take place on May 15, 2025, at 8:30 a.m. ET, following the release of the financial results [1]. - Dial-in numbers for the conference call include 646-307-1963 for New York and 800-715-9871 for USA & Canada, with a conference ID of 9822477 [2]. - A live webcast and replay of the conference call will be available on the company's Events & Presentations page [2].

Group 1 - Camtek Ltd. will release its financial results for the first quarter of 2025 on May 13, 2025 [1] - A video conference call will be hosted by the CEO, CFO, and COO on the same day at 9:00 am ET to discuss the results [2] - The call will be available for replay shortly after its conclusion through a provided link or on Camtek's website [3] Group 2 - Camtek is a developer and manufacturer of high-end inspection and metrology equipment for the semiconductor industry [4] - The company's systems inspect integrated circuits and measure features on wafers throughout the semiconductor production process [4] - Camtek serves demanding market segments including Advanced Interconnect Packaging, Heterogeneous Integration, and CMOS Image Sensors, among others [4]

Company Overview - KVH Industries, Inc. is a global leader in maritime and mobile connectivity, operating through the KVH ONE network [3] - The company was founded in 1982 and is headquartered in Middletown, RI, with research, development, and manufacturing operations also in Middletown and over a dozen offices worldwide [3] - KVH provides connectivity solutions for various sectors including commercial maritime, leisure marine, military/government, and land mobile applications, featuring product lines such as TracNet, TracPhone, and TracVision [3] Financial Results Announcement - KVH Industries will announce its financial results for the first quarter ending March 31, 2025, on May 7, 2025 [1] - An investor conference call will be held at 9:00 a.m. ET, hosted by CEO Brent Bruun and CFO Anthony Pike [1] Investor Engagement - A live broadcast of the conference call will be available online at investors.kvh.com, with an audio replay accessible for at least two weeks post-call [2] - Investors can submit questions during or after the call via email to IR@kvh.com [2]

WOODBURY, NY, May 05, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its first quarter 2025 financial results on Thursday, May 8, 2025. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 8, 2025 to discuss its first quarter 2025 financial and operating results, as well as recent developments. Who: Joseph M. Harary, President & CEODate/Time: Thursday, May 8, 2025, 4:30 PM ETDial-in Information: 1-888-334-5785Conferen ...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may b ...

LOUISVILLE, Ky., May 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended March 31, 2025 before the market open on Wednesday, May 14, 2025. A conference call to review the results is scheduled for Wednesday, May 14, 2025, at 9:00 am Eastern Time, which will include prepared remarks and materials from ...

Group 1 - PLBY Group, Inc. will report its first quarter 2025 financial results on May 15, 2025, after the U.S. stock market closes [1] - The company will publish a press release discussing the quarter and host a webcast for an analyst Q&A session at 5 p.m. Eastern Time [2] - PLBY Group is a global pleasure and leisure company, with its flagship brand, Playboy, recognized worldwide and driving billions in consumer spending across approximately 180 countries [3]

Financial Performance - TG Therapeutics reported U.S. net revenue of $119.7 million for BRIUMVI in the first quarter of 2025, representing approximately 137% growth compared to the same period last year [5][9] - The company raised its full-year 2025 global net revenue target to approximately $575 million, up from a prior guidance of $540 million, and increased the U.S. net revenue target for BRIUMVI to approximately $560 million from $525 million [1][10] - The net income for the first quarter of 2025 was $5.1 million, compared to a net loss of $10.7 million for the same period in 2024 [9][41] Product Development and Commercialization - BRIUMVI is experiencing growing adoption among healthcare providers, with positive feedback from both patients and clinicians, reinforcing the company's goal of making BRIUMVI the number one prescribed anti-CD20 treatment [2][5] - The company is investing in innovation, including simplifying the BRIUMVI treatment regimen and advancing subcutaneous BRIUMVI [2][5] - BRIUMVI is now commercially available in additional countries in the European Union, United Kingdom, and Switzerland, expanding its market presence [5][10] Clinical Trials and Research - Five-year data from the ULTIMATE I & II Phase 3 clinical trials showed that 92% of patients were free from disability progression after five years of treatment with BRIUMVI [5] - Ongoing clinical trials include a Phase 1 trial evaluating subcutaneous BRIUMVI and another for azer-cel in patients with primary progressive multiple sclerosis [6][10] - The ENHANCE Phase 3b clinical trial demonstrated that a single 600 mg BRIUMVI infusion was well tolerated, and rapid 30-minute infusions were also well received by patients [5][10] Financial Guidance and Future Outlook - The company anticipates a second quarter 2025 U.S. net product revenue target of $135 million and expects total operating expenses for the full year 2025 to be approximately $300 million [10][41] - TG Therapeutics plans to commence pivotal programs for subcutaneous BRIUMVI and based on improved dosing regimens evaluated in the ENHANCE trial [10][41] - The company aims to continue enrollment in ongoing clinical trials for BRIUMVI in autoimmune diseases outside of multiple sclerosis [10][41]

TORONTO, May 02, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (CBOE: MLC) (“Mount Logan” or the “Company”) will release its financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. The Company will host a conference call on Friday, May 16, 2025, at 11:00 a.m. Eastern Time to discuss these results. Shareholders, prospective shareholders, and analysts are welcome to listen to the conference call. To join the call, please use the dial-in information below. ...

Core Viewpoint - Greenlight Capital Re, Ltd. is set to release its financial results for the first quarter of 2025 on May 7, 2025, with a conference call scheduled for May 8, 2025, to discuss these results [1]. Group 1: Financial Results Announcement - The company will announce its first quarter financial results after market close on May 7, 2025 [1]. - A live conference call to discuss the financial results will take place on May 8, 2025, at 9:00 a.m. Eastern Time [1]. Group 2: Conference Call Details - Participants can join the conference call by dialing U.S. toll-free 1-877-407-9753 or international 1-201-493-6739 [2]. - The conference call will also be available via webcast [2]. - A telephone replay of the call will be accessible until May 13, 2025 [2]. Group 3: Company Overview - Greenlight Re provides multiline property and casualty insurance and reinsurance through its licensed entities in the Cayman Islands and Ireland [3]. - The company employs a non-traditional investment approach aimed at achieving higher long-term returns compared to traditional reinsurance investment strategies [3]. - Greenlight Re Innovations supports technology innovators in the (re)insurance sector by offering investment capital and risk capacity [3].